

Pediatric Joint Pain May Not Be Acute Arthritis

BY DAMIAN McNAMARA
Miami Bureau

AMELIA ISLAND, FLA. — Clinical acuity aids the differential diagnosis of acute arthritis in pediatrics, according to a presentation at a meeting on pediatrics for the primary care physician, sponsored by Nemours.

Dr. Carlos D. Rosé, chief of rheumatology, Alfred I. DuPont Hospital for Children, Wilmington, Del., offered tips for diagnosis of the following forms of pediatric arthritis:

► **Nonarticular disease.** Beware of reports of joint pain that are truly limb or marrow pain, Dr. Rosé said. "The patient will tell you [the] knee, elbow, etc. hurts, but you will determine by physical exam that it is not in the joint." Patients often describe limb pain as joint pain.

"Three to five times a year in my pediatric rheumatology practice I diagnose leukemia," Dr. Rosé said. Pain that is nocturnal, occurs when the patients move their arms or walk, and/or cannot be localized are among symptoms of marrow involvement. Because NSAIDs work for leukemic pain, patients might be taking ibuprofen around the clock, Dr. Rosé said. "If they stop and feel pain again at 4-6 hours, this is a red flag for bony pain."

Discomfort on limb compression, a "very abnormal" erythrocyte sedimentation rate (ESR), and absence of thrombocytosis are other signs of bony involvement, Dr. Rosé said.

► **Transient synovitis.** Transient synovitis can be severe and can signal the early phase of Legg-Calvé-Perthes disease, an idiopathic avascular necrosis of the femoral head. An ESR less than 40 mm/hr is diagnostic. Synovitis typically lasts 1-3 weeks and can be related to Legg-Calvé-Perthes disease or parvovirus.

Recurrent transient synovitis in some pediatric patients could be the onset of psoriasis or spondyloarthropathy, according to a multicenter study of 39 children with 102 episodes of transient synovitis (J. Rheumatol. 2006;33:810-11).

► **Intermittent monoarthritis.** Pediatric patients with intermittent arthritis often have a joint that gets swollen, the inflammation resolves in a few weeks, and then the joint gets swollen again. "Be patient with these patients. Just wait until the effusion goes away—most of the time it happens," Dr. Rosé said.

A big, bland effusion without a contracture is a presentation that is very suggestive of Lyme arthritis, he added.

► **Acute monoarthritis.** There are multiple etiologies for acute monoarthritis. Septic arthritis, while important, is overdiagnosed, Dr. Rosé said. Septic arthritis is usually monoarticular; exceptions are cases caused by gonococcus or tuberculosis and nontuberculosis mycobacterium.

Nonpyogenic infection, foreign bodies, pigmented villonodular synovitis, coagulopathy, and vascular abnormalities are other causes of monoarthritis. Trauma also can cause acute monoarthritis, especially among children who fall on their knees. The pain should not last more than 48 hours, Dr. Rosé said.

"Be careful—I had some children present for monoarthritis, and on physical examination I found other areas of inflammation, such as the toes or knees. Look for a second joint to get away from the idea that it is monoarticular," Dr. Rosé said.

► **Migratory arthritis.** This condition is an orderly involvement of primarily intermediate joints, approximately one per day, characterized by periarticular swelling. It is a sequential form of "polyarticular monoarthritis," Dr. Rosé said.

Migratory arthritis often is very painful but responsive to NSAIDs. Etiology is overwhelmingly postinfectious, he added.

► **Acute polyarticular arthritis.** "This is very important to recognize. Here every joint is painful in 1 day, it is not sequential," Dr. Rosé said. Parvovirus infection is the most common cause. Approximately one-third present with an intense red rash in a symmetrical pattern on both hands and feet. Small epidemics often occur in springtime, he added. Common viral dis-

eases such as Epstein-Barr virus, cytomegalovirus, hepatitis, and infections caused by *Clostridium difficile* can produce arthritis, Dr. Rosé said.

► **Rheumatic fever.** Diagnostic tips include a fever of 101.3° F daily and an ESR of greater than 50 mm/hr. The patient will look ill and a cardiac examination will demonstrate tachycardia, gallop, and murmurs. Order echocardiography within the first week for all cases of suspected rheumatic fever, Dr. Rosé suggested. ■

NOW AVAILABLE

NEW
OPANA®
(oxymorphone HCl) 

Tablets

OPANA® is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate.

NEW
OPANA® ER
(oxymorphone HCl) 

Extended-release tablets

OPANA® ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid therapy for an extended period of time.

- OPANA® ER is not intended for use as a prn analgesic.
- OPANA® ER is not indicated for pain in the immediate postoperative period (12-24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists.
- OPANA® ER is not indicated for pain in the postoperative period if the pain is mild or not expected to persist for an extended period of time.

Important Safety Information

OPANA® and OPANA® ER are opioid agonists and Schedule II controlled substances with an abuse liability similar to morphine. OPANA® and OPANA® ER can be abused in a manner similar to other opioid agonists, legal or illicit.

OPANA® ER has a boxed warning as follows:

WARNING: OPANA® ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OPANA® ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OPANA® ER is an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

OPANA® ER is NOT intended for use as a prn analgesic.

OPANA® ER TABLETS are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed OPANA® ER TABLETS leads to rapid release and absorption of a potentially fatal dose of oxymorphone.

Patients must not consume alcoholic beverages, or prescription or nonprescription medications containing alcohol, while on OPANA® ER therapy. The co-ingestion of alcohol with OPANA® ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

OPANA® and OPANA® ER are contraindicated in patients with a known hypersensitivity to oxymorphone hydrochloride, morphine analogs such as codeine, or any of the other ingredients of OPANA® and OPANA® ER; in patients with moderate or severe hepatic impairment or in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), acute or severe bronchial asthma, hypercarbia, and in any patient who has or is suspected of having paralytic ileus.

Respiratory depression is the chief hazard of OPANA® and OPANA® ER, particularly in elderly or debilitated patients. OPANA® and OPANA® ER should be administered with extreme caution to patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma.

Patients receiving other opioid analgesics, general anesthetics, phenothiazines or other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) may experience additive effects resulting in respiratory depression, hypotension, profound sedation, or coma.

OPANA® and OPANA® ER should be used with caution in elderly and debilitated patients and in patients who are known to be sensitive to CNS depressants, such as those with cardiovascular, pulmonary, renal, or hepatic disease. OPANA® and OPANA® ER should be used with caution in patients with mild hepatic impairment and in patients with moderate to severe renal impairment. These patients should be started cautiously with lower doses of OPANA® or OPANA® ER while carefully monitoring for side effects.

OPANA® ER is not indicated for preemptive analgesia (administration preoperatively for the management of postoperative pain).

The most common adverse drug reactions (≥10%) reported at least once by patients treated with OPANA® in all clinical trials were nausea and pyrexia. The most common adverse drug reactions (≥10%) in all clinical trials for OPANA® ER were nausea, constipation, dizziness (excluding vertigo), vomiting, pruritus, somnolence, headache, increased sweating, and sedation.

Please see accompanying Brief Summaries of full Prescribing Information, including boxed warning on OPANA® ER, on the following pages.